Combination therapies targeting PD-1, TIM-3, and LAG-3
This disclosure relates to combination therapies targeting two or all of PD-1, TIM-3, and LAG-3 using antibodies specific for these targets in patients who are in need of enhanced immunity. Also included in the disclosure are compositions useful in the therapies. The therapies are useful in treating diseases such as cancers.
1. A method of enhancing immunity in a human patient in need thereof, comprising administering to the patient pembrolizumab or nivolumab in combination with an anti-TIM-3 antibody or an antigen-binding portion thereof that comprises:
a) H-CDR1-3 and L-CDR1-3 that comprise the amino acid sequences of SEQ ID NOs: 8-13, respectively;
b) a heavy chain variable domain (VH) and a light chain variable domain (VL) that comprise the amino acid sequences of SEQ ID NOs: 7 and 4, respectively; or
c) a heavy chain (HC) that comprises the amino acid sequences of SEQ ID NOs: 7 and 377 and a light chain (LC) that comprises the amino acid sequences of SEQ ID NOs: 4 and 378.
2. The method of claim 1 , wherein the patient has cancer.
3. The method of claim 2 , wherein the cancer is selected from the group consisting of leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, myeloma, melanoma, non-small cell lung cancer, bladder cancer, gallbladder cancer, head and neck squamous cell carcinoma, esophageal cancer, gastroesophageal cancer, gastric cancer, ovarian cancer, colorectal cancer, renal cell carcinoma, pancreatic cancer, Merkel cell carcinoma, fibrosarcoma, gliosarcoma, mesothelioma, biliary tract cancer, and glioblastoma.
4. The method of claim 1 , further comprising administering to the patient radiation therapy, a chemotherapeutic agent, an anti-neoplastic agent, or an anti-angiogenic agent.
5. The method of claim 1 , further comprising administering irinotecan to the patient.
6. A method of enhancing immunity in a human patient in need thereof, comprising administering to the patient an anti-PD-1 antibody or an antigen-binding portion thereof and an anti-TIM-3 antibody or an antigen-binding portion thereof, wherein
I) the anti-PD-1 antibody comprises:
a) heavy chain complementarity-determining regions (H-CDR) 1-3 and light chain complementarity-determining regions (L-CDR) 1-3 comprising the amino acid sequences of SEQ ID NOs: 228-233, respectively;
b) a heavy chain variable domain (VH) and a light chain variable domain (VL) comprising the amino acid sequences of SEQ ID NOs: 226 and 227, respectively; or
c) a heavy chain (HC) and a light chain (LC) comprising the amino acid sequences of SEQ ID NOs: 226 and 375, and SEQ ID NOs: 227 and 379, respectively; and
II) the anti-TIM-3 antibody comprises:
a) H-CDR1-3 and L-CDR1-3 comprising the amino acid sequences of SEQ ID NOs: 8-13, respectively;
b) a VH and a VL comprising the amino acid sequences of SEQ ID NOs: 7 and 4, respectively; or
c) an HC and an LC comprising the amino acid sequences of SEQ ID NOs: 7 and 377; and SEQ ID NOs: 4 and 378; respectively.
7. The method of claim 6 , wherein the patient has cancer.
8. The method of claim 7 , wherein the cancer is selected from the group consisting of leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, myeloma, melanoma, non-small cell lung cancer, bladder cancer, gallbladder cancer, head and neck squamous cell carcinoma, esophageal cancer, gastroesophageal cancer, gastric cancer, ovarian cancer, colorectal cancer, renal cell carcinoma, pancreatic cancer, Merkel cell carcinoma, fibrosarcoma, gliosarcoma, mesothelioma, biliary tract cancer, and glioblastoma.
9. The method of claim 6 , further comprising administering to the patient radiation therapy, a chemotherapeutic agent, an anti-neoplastic agent, or an anti-angiogenic agent.
10. The method of claim 6 , further comprising administering irinotecan to the patient.
11. A method of treating cancer in a human patient, comprising administering to the patient pembrolizumab; an anti-TIM-3 antibody comprising an HC that comprises the amino acid sequences of SEQ ID NOs: 7 and 377 and an LC that comprises the amino acid sequences of SEQ ID NOs: 4 and 378; and irinotecan.
12. The method of claim 11 , wherein the cancer is selected from the group consisting of leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, myeloma, melanoma, non-small cell lung cancer, bladder cancer, gallbladder cancer, head and neck squamous cell carcinoma, esophageal cancer, gastroesophageal cancer, gastric cancer, ovarian cancer, colorectal cancer, renal cell carcinoma, pancreatic cancer, Merkel cell carcinoma, fibrosarcoma, gliosarcoma, mesothelioma, biliary tract cancer, and glioblastoma.
13. The method of claim 11 , further comprising administering to the patient radiation therapy, a chemotherapeutic agent, an anti-neoplastic agent, or an anti-angiogenic agent.
14. A method of treating cancer in a human patient, comprising administering to the patient nivolumab; an anti-TIM-3 antibody comprising an HC that comprises the amino acid sequences of SEQ ID NOs: 7 and 377 and an LC that comprises the amino acid sequences of SEQ ID NOs: 4 and 378; and irinotecan.
15. The method of claim 14 , wherein the cancer is selected from the group consisting of leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, myeloma, melanoma, non-small cell lung cancer, bladder cancer, gallbladder cancer, head and neck squamous cell carcinoma, esophageal cancer, gastroesophageal cancer, gastric cancer, ovarian cancer, colorectal cancer, renal cell carcinoma, pancreatic cancer, Merkel cell carcinoma, fibrosarcoma, gliosarcoma, mesothelioma, biliary tract cancer, and glioblastoma.
16. The method of claim 14 , further comprising administering to the patient radiation therapy, a chemotherapeutic agent, an anti-neoplastic agent, or an anti-angiogenic agent.